Respira Therapeutics, Inc.

Revati Shreeniwas

Zhen Xu

Martin J Donovan

Robert Curtis

Hugh Smyth

Jeffry G Weers

Alain Romero

Adaani Frost

Dan Deaton

James Hannon

Aileen Gibbons

Stephen Lermer

Novel dry powder compositions comprising and methods relating thereto are provided. The dry powder compositions comprise PDE5 inhibitors, such as vardenafil, or pharmaceutically acceptable salts or esters thereof. The dry powder compositions may optionally include an carrier/excipient. The concentration of active agent may be at least about 2% by weight. Methods of aerosolizing the dry powder compositions and using them to treat various diseases are also disclosed.

PDE5 inhibitor powder formulations and methods relating thereto

Provided herein are methods for treating pulmonary hypertension. The methods include administering to a subject in need thereof an effective amount of a vasodilator, wherein the vasodilator is administered to the subject via inhalation pro re nata using a portable inhaler. In some embodiments, the vasodilator is a PDE5 inhibitor. Pharmaceutical compositions for pro re nata administration of vasodilators are also described.

Methods and compositions for treatment of pulmonary hypertension and other lung disorders

Methods for treatment of pulmonary hypertension

Growing community of inventors

Palo Alto, CA, United States of America

Revati Shreeniwas